105905-60-0

Basic information

• Product Name: 3,4-DIETHOXY-BENZOYL CHLORIDE
• Synonyms: 3,4-DIETHOXY-BENZOYL CHLORIDE;benzoyl chloride, 3,4-diethoxy-
• CAS NO: 105905-60-0
• Molecular Formula: C₁₁H₁₃ClO₃
• Molecular Weight: 228.67
• Mol File: 105905-60-0.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 3,4-DIETHOXY-BENZOYL CHLORIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 3,4-DIETHOXY-BENZOYL CHLORIDE(105905-60-0)
• EPA Substance Registry System: 3,4-DIETHOXY-BENZOYL CHLORIDE(105905-60-0)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 105905-60-0(Hazardous Substances Data)

Upstream product

• 5409-31-4 3,4-diethoxybenzoic acid 

Downstream Products

• 99499-11-3 3,4-Diethoxy-N-propyl-benzamide 
• 1477751-75-9 N-(4-((3-chlorophenyl)amino)quinazolin-6-yl)-3,4-diethoxybenzamide 
• 1608146-63-9 N-(4-(5-(3,4-diethoxyphenyl)-1,2,4-oxadiazol-3-yl)-2-iodophenyl)acetamide 
• 333322-82-0 2-(3,4-diethoxyphenyl)-5-(pyridin-4-yl)-1,3,4-oxadiazole 
• 568544-09-2 N-[(3,4-diethoxyphenyl)carbonyl]glycine 
• 102762-85-6 6,7-diethoxy-1-(3,4-diethoxy-phenyl)-3,4-dihydro-isoquinoline 
• 42420-04-2 3,4-Diethoxy-N-isobutyl-benzamide 
• 122892-62-0 N-[4-(2-Dimethylamino-ethoxy)-benzyl]-3,4-diethoxy-benzamide 
• 42420-19-9 4-(3,4-diethoxy-benzoyl)-morpholine 
• 101108-33-2 3,4-diethoxy-benzoic acid diethylamide 
• 349446-71-5 3,4-diethoxy-benzoic acid amide 
• 855269-82-8 3,4-diethoxy-benzoic acid-(4-ethoxy-3-methoxy-phenethylamide) 
• 905808-34-6 3,4-diethoxy-benzoic acid-(3,4-diethoxy-phenethylamide) 

Relevant articles and documents

Synthesis and structure-activity relationship of non-peptidic antagonists of neuropilin-1 receptor

Neuropilins (NRPs) are VEGF-A165 co-receptors over-expressed in tumor cells, and considered as targets in angiogenic-related pathologies. We previously identified compound 1, the first non-peptidic antagonist of the VEGF-A165/NRP binding, which exhibits in vivo anti-angiogenic and anti-tumor activities. We report here the synthesis and biological evaluations of new antagonists structurally-related to compound 1. Among these molecules, 4a, 4c and 4d show cytotoxic effects on HUVEC and MDA-MB-31 cells, and antagonize VEGF-A165/NRP-1 binding. This study confirmed our key structure-activity relationships hypothesis and paved the way to compound 1 'hit to lead' optimization.

Design, synthesis, and evaluation of substituted 6-amide-4- anilinoquinazoline derivatives as c-Src inhibitors

The 4-anilinoquinazoline scaffold has been historically used for designing EGFR/VEGFR/HER2 inhibitors while it has not been reported widely for developing c-Src inhibitors. Thus, a series of novel 4-anilinoquinazoline derivatives grafting different amide moieties at the 6-position were designed and synthesized as potential inhibitors for c-Src. In this manuscript, all of the designed compounds were screened via molecular docking using Discovery Studio 3.5 software. As expected, the results of the docking study revealed that most of these targeted compounds possessed lower binding energy than the positive control Saracatinib. Subsequently, all of the screened compounds were synthesized and evaluated for their c-Src in vitro inhibitory activities and in vitro antiproliferation assays against four human cancer cells (A549, MCF-7, HepG-2, HeLa). Among these compounds, 24 exhibited the most potent inhibitory activity against c-Src kinase as well as at the cellular level, of which the IC50 value reached up to 2.9 nM, comparable to the positive compound Saracatinib. Kinase selectivity profile also demonstrated that compound 24 showed good selectivity over several close kinase targets. These results, along with relative 3D-QSAR study, could provide an important basis for further development of compound 24 as a potent tyrosine kinase inhibitor.

Small-Molecule Choline Kinase Inhibitors as Anti-Cancer Therapeutics

Small molecule choline kinase inhibitors having the following formula: are provided herein. Also provided herein are pharmaceutical compositions containing Formula I compounds, together with methods of treating cancer, methods of inhibiting choline kinase enzymatic activity, and methods of treating tumors by administering an effective amount of a Formula I compound.

Pharmacological validation of trypanosoma brucei phosphodiesterases B1 and B2 as druggable targets for African sleeping sickness

Neglected tropical disease drug discovery requires application of pragmatic and efficient methods for development of new therapeutic agents. In this report, we describe our target repurposing efforts for the essential phosphodiesterase (PDE) enzymes TbrPDEB1 and TbrPDEB2 of Trypanosoma brucei, the causative agent for human African trypanosomiasis (HAT). We describe protein expression and purification, assay development, and benchmark screening of a collection of 20 established human PDE inhibitors. We disclose that the human PDE4 inhibitor piclamilast, and some of its analogues, show modest inhibition of TbrPDEB1 and B2 and quickly kill the bloodstream form of the subspecies T. brucei brucei. We also report the development of a homology model of TbrPDEB1 that is useful for understanding the compound-enzyme interactions and for comparing the parasitic and human enzymes. Our profiling and early medicinal chemistry results strongly suggest that human PDE4 chemotypes represent a better starting point for optimization of TbrPDEB inhibitors than those that target any other human PDEs.

Novel acyl coenzyme A: Diacylglycerol acyltransferase 1 inhibitors - Synthesis and biological activities of N-(substituted heteroaryl)-4-(substituted phenyl)-4-oxobutanamides

In a program to discover new small molecule diacylglycerol acyltransferase (DGAT)-1 inhibitors, screening of our in-house chemical library was carried out using recombinant human DGAT-1 enzyme. From this library, the lead compound 1a was identified as a n

NOVEL MODULATORS OF SPHINGOSINE PHOSPHATE RECEPTORS

Compounds that activate a sphingosine-1-phosphate receptor of the subtype 1 are provided. Certain compounds selectively activate the receptor subtype 1 in relation to the sphinogosine-1-phosphate receptor subtype 3. Uses and methods of inventive compounds

Synthesis, gastrointestinal prokinetic activity and structure-activity relationships of novel N-[[2-(dialkylamino)ethoxy]benzyl]benzamide derivatives

Novel N-[[2-(dialkylamino)ethoxy]benzyl]benzamide derivatives (II-1-51), derived from the structural modification of metoclopramide (1), were synthesized and examined for their pharmacological activities. Among them, N-[4-[2-(dimethylamino)ethoxy]benzyl]-3,4-dimethoxybenzamide (II-34) which exhibited well balanced gastrointestinal prokinetic and antiemetic activities was selected as a new type of gastrointestinal prokinetic agent.